learndrugs
Mental & Behavioral Health

Bipolar Disorder

High-yield Verified · Sep 2026

Bipolar disorder is a mood disorder of recurring manic or hypomanic episodes alternating with depression — bipolar I requires at least one manic episode, while bipolar II requires a hypomanic episode plus a major depressive episode and no mania.

The disorder behind 7 days versus 4 days, DIG FAST, the hospitalization override, the 5-to-10-year diagnostic delay, the finger-food care plan, and the reason a patient on lithium must not suddenly change how much salt they eat.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 The arithmetic that sorts the spectrum — 7 days, 4 days, and one hospital admission

Bipolar disorder is "a chronic mood disorder characterized by recurrent episodes of mania, hypomania, and depression, often interspersed with periods of relative euthymia," and it is often misdiagnosed at first. The family includes bipolar I, bipolar II, cyclothymic disorder, and the other-specified and unspecified categories. Mania means at least 7 days in a row of an abnormally high or irritable mood together with raised energy and activity — or an episode of any length that needs hospital admission. Hypomania is the same picture for at least 4 days in a row. Both carriers agree on those numbers across two DSM editions, so the pair is safe to teach: seven days for mania, four for hypomania.

Then the override that catches students out: if the symptoms require hospitalization, the episode counts as mania rather than hypomania, even when it has lasted less than a week. The count rule is equally specific — three or more of the seven criteria symptoms are required, but if the mood is irritable rather than elevated, at least four are needed. The seven are inflated self-esteem or grandiosity; decreased need for sleep; a compulsion to keep talking; flight of ideas or racing thoughts; high distractibility; increased goal-directed activity or psychomotor agitation; and risky activities with a high chance of painful consequences — for example spending sprees, sexual risk-taking or reckless business investments. The sourced mnemonic is DIG FAST: Distractibility, Irresponsibility or Irritability, Grandiosity, Flight of ideas, Activity, Sleep decreased, Talkativeness.

Three things separate mania from hypomania, and duration is only one of them. Severity — manic symptoms disrupt work or social functioning or need hospital admission, whereas hypomania does not cause major impairment. Psychosis — hypomania has no psychosis; if psychosis is present, the episode is mania by definition. Duration — seven days against four. Hypomania still has to be real enough to see: it requires a clear change in functioning that is out of character for the person and noticeable to others. The diagnostic consequence is enormous: because bipolar I disorder is defined by manic episodes (NIMH), a single manic episode can turn what looked like depression into a diagnosis of bipolar disorder.

The duration and count arithmetic. Seven days or a hospital admission makes it mania; four days without impairment or psychosis makes it hypomania — and a single manic episode is all bipolar I requires.

02 An unrestrained amygdala — and honest uncertainty about everything upstream

Start with what the current sources actually say: bipolar disorder "is a complex and heterogeneous mood disorder with a multifactorial etiology involving genetic vulnerability, neurobiological alterations, environmental stressors, and medical or substance-related contributors," and its pathophysiology "is complex and multifactorial, involving dysregulation across genetic, molecular, cellular, neural circuit, immune, metabolic, and circadian systems." Serotonin, dopamine and noradrenaline still matter — in mania, increased dopaminergic transmission in mesolimbic pathways tracks with elevated mood, reward-seeking and impulsivity — but "contemporary evidence indicates that neurotransmitter abnormalities are better understood as downstream manifestations of broader network dysregulation." A page that presents bipolar disorder as a solved serotonin problem is inventing a certainty the field does not have.

What is measurable sits below the synapse and above the circuit. Genome-wide studies converge on calcium signalling — CACNA1C, which encodes an L-type calcium channel, "has emerged as one of the most consistently replicated susceptibility genes" — and the nursing text makes the drug-list connection: "newer research indicates altered intracellular calcium signaling occurs in people with bipolar disorders, and antiseizure medications can provide effective treatment," the sourced reason anticonvulsants belong on a mood-disorder drug list at all. Brain-derived neurotrophic factor "is consistently reduced during acute manic and depressive episodes and may partially normalize with treatment," alongside mitochondrial dysfunction, oxidative stress, chronic low-grade inflammation and circadian clock-gene abnormalities. Lithium acts in the same territory, inhibiting glycogen synthase kinase-3β and affecting inositol-dependent second messenger systems, circadian regulation and the hypothalamic–pituitary–adrenal axis.

The circuit finding is the one to draw. Functional MRI studies have repeatedly shown amygdala hyperactivation during emotional processing, "particularly during manic and depressive episodes," while "the dorsolateral and ventrolateral prefrontal cortices often exhibit reduced activation, reflecting impaired top-down regulation of limbic activity." An earlier review states the consequence plainly: "This increased activity in the amygdala along with decreased activity in cortical regions may be the reason why the executive function is impaired in mania while the emotions are heightened and unrestrained." Structurally, the ENIGMA Bipolar Disorder Working Group reports abnormal cortical thickness and subcortical volumes across fronto-limbic circuits, and diffusion imaging shows reduced white-matter integrity in the tracts linking the prefrontal cortex with the amygdala. Put together: emotion amplified, and the brake that normally restrains it running weak — which is grandiosity, impulsivity and the conviction that three hours of sleep was plenty.

The bipolar chain: genetic loading and early adversity alter neurotrophic and calcium signalling, producing a hyperactive amygdala against a hypoactive prefrontal cortex — emotion amplified with the brake off.

03 Why bipolar depression is called unipolar depression for five to ten years

The diagnostic delay is quantified and it is shocking. Current literature reports "an average delay of 5 to 10 years between first psychiatric contact and correct diagnosis, largely due to depressive polarity predominance at onset and underreporting of hypomanic symptoms." The reason is structural, not careless: "cross-sectionally, bipolar depression is typically indistinguishable from unipolar depression." The five-symptoms-for-two-weeks rule that defines a major depressive episode is identical inside bipolar disorder, so a patient in a depressive episode looks exactly like a patient with major depressive disorder — and because the illness so often opens with depression, depression is usually what brings them in.

The only thing that separates them is history, which means it is the interview that makes the diagnosis. "The most critical diagnostic task is the systematic elicitation of past manic or hypomanic episodes, as these are often not spontaneously reported by patients." Features that raise suspicion of bipolar disorder in a patient presenting with depression: depression beginning early, especially before age 25; recurrent, high-frequency depressive episodes; psychotic features; postpartum mood episodes; a strong family history of bipolar disorder; and mood switching or activation on an antidepressant.

How often does that change happen? State the figure with its window and its owner, because the denominators differ. StatPearls’ bipolar chapter reports that "estimates of patients transitioning to bipolar disorder within 3 years of an MDD diagnosis range from 20% to 30%," and separately that subthreshold hypomanic symptoms occur in as many as 40% of patients with major depressive disorder — symptoms, not a diagnosis. Those are answers to narrower questions than "what fraction of depressed people turn out to be bipolar," and they should never be quoted without the three-year window attached. Screening helps but does not settle it: the Mood Disorders Questionnaire has 80% sensitivity and 70% specificity, the Hypomania Checklist 32 has 82% sensitivity and 57% specificity, and the sourced instruction is that they are "adjuncts rather than diagnostic instruments, with positive results prompting structured clinical interviews" — a positive screen opens the assessment, it does not close it.

04 Lithium travels the sodium pathway — which turns a stomach bug into a neurologic emergency

One pharmacokinetic sentence explains every lithium safety rule on this page. Lithium is "neither protein-bound nor metabolized and is almost entirely eliminated by renal excretion" through glomerular filtration and tubular sodium-coupled reabsorption. The glomerulus filters it freely, and "the proximal tubule reabsorbs 80% of it via sodium transport pathways." Consequently "even minor changes in volume status, renal perfusion, or sodium balance can produce clinically significant changes in serum lithium concentrations." The kidney cannot tell lithium and sodium apart, so anything that makes the body conserve sodium makes it conserve lithium too.

That yields four routes to toxicity, and the commonest is not overdose. Reduced renal function — chronic kidney disease, acute kidney injury, older age. Volume or sodium depletion — "because the kidney handles lithium similarly to sodium, states of sodium or volume depletion increase renal lithium reabsorption and decrease excretion," including dehydration, vomiting, diarrhea, fever, lithium-induced nephrogenic diabetes insipidus and low-sodium diets. Medication interactions — NSAIDs, thiazide diuretics, ACE inhibitors and angiotensin receptor blockers, with metronidazole added by a second source. Excess intake. And the summary line: "lithium toxicity most commonly results from reduced renal clearance rather than excessive ingestion."

The pattern matters more than the number, and this is where the reasoning gets counter-intuitive. Chronic toxicity "is the most common pattern and is usually unintentional." Patients with acute toxicity "are more likely to be asymptomatic despite high lithium concentrations" and present with gastrointestinal symptoms first, while chronic and acute-on-chronic toxicity involve sustained tissue accumulation and are "more often associated with neurologic symptoms even at relatively lower lithium concentrations." Worse, "because lithium distribution into the central nervous system occurs slowly, neurologic symptoms may develop even as serum lithium concentrations decline." So the clinical rule outranks the laboratory: "any patient who is prescribed or has access to lithium and develops vomiting, confusion, or cerebellar signs should be presumed to have lithium toxicity until proven otherwise."

Lithium rides the sodium transporter. Anything that depletes volume or sodium makes the kidney conserve both, so the level rises without a dose change — and in chronic toxicity the neurologic damage outruns the number.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Heritability — twin and family heritability estimates of 60% to 85%, up to 80% of monozygotic twins are concordant, and almost two-thirds of patients have at least one close relative with bipolar disorder or unipolar depression Age — onset most commonly in adolescence and early adulthood: one systematic review found the largest group beginning at 14–21 years, US annual prevalence is highest at 18–29 years, and onset after 60 is rare Early-life adversity — childhood trauma, maltreatment, parental loss or severe psychosocial stress, linked to earlier onset, a more severe course and more comorbidity Other named life events — childbirth, divorce, unemployment, disability and early parental loss A stressful life event — more than 60% of patients report at least one in the 6 months before a manic or depressive episode modifiable Sleep loss — decreased need for sleep is one of the warning signs of a manic episode that patients learn to recognize, and a regular sleep routine is part of self-management modifiable Antidepressants and corticosteroids — both named as triggers of a manic episode; an antidepressant without a mood stabiliser risks a switch modifiable Alcohol, cannabis, stimulants such as cocaine and amphetamines, and corticosteroids — they can precipitate mood episodes and mimic mania modifiable Stimulants and caffeine, and excessive steroid or human growth hormone use — both triggers and mimics of mania modifiable Sex does not change the risk but changes the pattern — prevalence is similar in men and women, but women more often have bipolar II, depressive predominance, rapid cycling and mixed features, and men more often present first with mania and have more comorbid substance use Metabolic comorbidity — one-third to one-half of patients meet criteria for metabolic syndrome, obesity rates significantly exceed the general population, and metabolic syndrome is linked to greater illness severity, more frequent recurrence and increased suicidality modifiable

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Decreased need for sleep — feeling rested after about three hours early Hold & notify
Why: This is a criterion symptom, not insomnia: the patient is not tired. It is also the single most useful early-warning sign, which is why patients are taught to "recognize mood swings and warning signs for manic episodes such as decreased need for sleep." The relationship runs both ways — sleep loss also triggers mania, which is why stabilising sleep and wake routines is itself a treatment.
Grandiosity and inflated self-esteem, up to frank grandiose delusions Hold & notify
Why: One of the seven criteria symptoms, and it escalates. Delusional content is mood-congruent: "grandiose delusions, believing they are high-level operatives such as spies, government officials, members of secret agencies," and delusions of paranoia about being stalked or surveilled. These patients "are highly unlikely to respond to outsiders’ views" on either the psychosis or the mania.
Rapid, pressured speech with flight of ideas and racing thoughts Hold & notify
Why: The mental-status signature of mania alongside distractibility, increased goal-directed activity and psychomotor agitation. Its nursing consequence is practical: attention span and focus are impaired, so assessment and teaching both have to use short, clear, concrete statements and expect rapid topic changes.
Risky activities with a high chance of painful consequences — spending sprees, sexual risk-taking, reckless business investments Hold & notify
Why: A criterion symptom, and the one families actually report: patients "commonly engage in goal-directed activities that may result in harmful consequences, such as spending excessive money, starting businesses unprepared, traveling, or promiscuity." "Those suffering from mania often act with impropriety, ruining reputations and careers." Nursing assessment includes whether external controls are needed to protect the client from consequences such as bankruptcy.
Irritability, aggression and property damage rather than euphoria Report immediately
Why: Many patients "engage in property damage or even harm themselves or others through verbal or physical assaults. They may also become highly aggressive, agitated, or irritable." The criteria account for this: if the mood is irritable rather than elevated, four symptoms are required instead of three. Mania is a medical emergency and often requires psychiatric hospitalization.
Poor insight — the patient does not see a problem; everyone around them does Hold & notify
Why: "Generally, the individuals themselves do not realize what is happening (poor insight). The problem is mainly noticed by others, including family members, friends, and even strangers or police." Insight is particularly poor in hypomania, where nothing feels wrong at all. The practical consequence: "it is often helpful to interview family members or significant others," because the patient’s own history is unreliable.
Not eating or sleeping for days with physical exhaustion Report immediately
Why: "People experiencing a manic episode may become physically exhausted," and "the client may not eat or sleep for days at a time with potential physiological consequences." This is why the acute nursing goals are stable cardiac status, good hydration, sufficient sleep and rest, and intact tissue integrity, and why the laboratory follow-up includes sodium, hematocrit, albumin and prealbumin — nutrition labs that become abnormal because of the mania itself.
Manic psychosis — hallucinations and delusions appearing only within a mood episode Report immediately
Why: StatPearls: "Mania also commonly presents with psychotic features, which include delusions or hallucinations," and psychotic symptoms during severe mania or depression can result in "an incorrect diagnosis of schizophrenia." The discriminator is timing: if psychosis occurs only during mood episodes, the diagnosis is the mood disorder. Note that psychosis in an episode means it is mania, not hypomania, by definition.
The depressive pole — slowed thinking, physical fatigue, hopelessness and withdrawal Hold & notify
Why: "Unlike the increased energy and impulsive behaviors of a manic episode, depressive episodes are characterized by slowed thinking, physical fatigue, and feelings of hopelessness," with difficulty performing basic daily tasks. depressive symptoms account "for the majority of symptomatic burden and disability," which is precisely why the disorder is first labelled unipolar depression.
Suicidal ideation during a depressive episode Report immediately
Why: "Bipolar depression accounts for the majority of the symptomatic burden and is associated with the highest risk of suicide in bipolar disorder," and "most suicide attempts and completed suicides occur during depressive or mixed episodes rather than during manic episodes." The magnitude: lifetime suicide attempt rates are estimated at 25% to 50%, and the mortality ratio from suicide is 20 times above the general population rate, exceeding other mental health disorders.
Mixed features — depressed mood, guilt or thoughts of death inside a manic episode, or grandiosity and reduced need for sleep inside a depressive one Hold & notify
Why: A specifier requiring full criteria for one pole plus three or more symptoms of the other, present on most days. In a manic episode the added features are depressed mood, anhedonia, psychomotor retardation, fatigue, excessive guilt or recurrent thoughts of death; in a depressive episode they are expansive mood, grandiosity, increased talkativeness, flight of ideas, increased goal-directed activity, painful-consequence activities and decreased need for sleep.
Fine hand tremor, polyuria and mild thirst in a patient on lithium Expected
Why: Expected and persistent: "fine hand tremor, polyuria, and mild thirst may persist throughout treatment." The polyuria reflects lithium-induced nephrogenic diabetes insipidus. The distinction that matters is tremor quality: a fine tremor is expected, a coarse tremor is toxicity.
Vomiting, diarrhea, drowsiness, coarse tremor, slurred speech or unsteady gait in a patient on lithium Report immediately
Why: The toxicity ladder. Gastrointestinal symptoms come first in acute toxicity; the neurologic system is the most commonly affected, especially in chronic toxicity — drowsiness, coarse tremor, slurred speech, hyperreflexia, agitation, muscle weakness, nystagmus and ataxia, progressing to mental status change, seizures, delirium and coma. The rule: vomiting, confusion or cerebellar signs in anyone with access to lithium is toxicity until proven otherwise.
Tinnitus and a large output of dilute urine on lithium Report immediately
Why: The nursing version of the same ladder: early toxicity is "diarrhea, vomiting, drowsiness, muscular weakness, and lack of coordination," and "at higher levels giddiness, ataxia, blurred vision, tinnitus, and a large output of dilute urine may be seen." These are on the report-immediately list patients are given at discharge.
New-onset mania in a patient over 50, or over 60 Hold & notify
Why: "Onset of bipolar disorder after age 60 is rare," and new manic symptoms in an older adult "should be communicated to the health care provider for investigation of medical causes such as stroke, thyroid dysfunction, or dementia." First onset after 50 is one of the features that should raise suspicion of a secondary cause, alongside abrupt onset, no personal or family psychiatric history, neurologic abnormalities, cognitive impairment, fluctuating consciousness, a new medical illness, onset after a medication exposure, and poor response to evidence-based treatment. The sourced action is that this "should be communicated to the health care provider for investigation" — an urgent referral, not a resuscitation.

Diagnostics

Test In this disorder Normal
There is no test — the diagnosis is clinical The collateral history is not a courtesy, it is a data source — poor insight in mania and hypomania makes the patient an unreliable historian about the very episodes the diagnosis depends on "Bipolar disorder is a clinical diagnosis that relies on careful longitudinal history and mental status examination, as no biomarker or neuroimaging modality has adequate sensitivity or specificity for routine diagnostic use." Accurate diagnosis requires identifying lifetime episodes of mania, hypomania, depression and mixed states, "ideally corroborated by collateral informants and prior treatment records." —
Initial medical work-up to exclude a secondary cause Hyperthyroidism is the classic mimic — "Physiologic conditions that may mimic mania include hyperthyroidism, hypertensive urgency, hypercortisolemia, hyperaldosteronism," and "A complete blood count (CBC), complete metabolic panel (CMP), thyroid panel, and a urine drug screen are some of the basic laboratory values needed in assessing a manic patient." Other mimics: stimulant, cocaine, amphetamine, PCP and nicotine intoxication; hallucinogens; excessive steroid or growth hormone use; hypertensive urgency; hypercortisolemia Complete blood count · comprehensive metabolic panel · TSH and thyroid hormones · vitamin B12 and folate · urine toxicology · liver and renal function · pregnancy testing when indicated. Brain imaging by CT or MRI where an organic cause is suspected, "especially in elderly or very young patients"; routine neuroimaging is not recommended for diagnosis —
Red flags for a secondary cause of mania Any one of these should redirect the workup toward a medical cause before a psychiatric label is applied. In an older adult presenting with new mania, investigate stroke, thyroid dysfunction and dementia First onset after age 50 · abrupt onset · no personal or family psychiatric history · neurologic abnormalities · cognitive impairment · fluctuating consciousness · a new medical illness · onset after a medication exposure · poor response to evidence-based treatment —
Unipolar versus bipolar depression — the history questions The problem is structural: "cross-sectionally, bipolar depression is typically indistinguishable from unipolar depression," and past hypomanic or manic episodes "are often not spontaneously reported by patients" — so they must be asked about directly. The average delay to a correct diagnosis is 5 to 10 years. On conversion, quote the figure with its window and owner: StatPearls reports 20% to 30% transitioning within 3 years of a major depressive disorder diagnosis, and separately that subthreshold hypomanic symptoms occur in up to 40% of patients with major depressive disorder — symptoms, not a diagnosis Features that raise suspicion of bipolar disorder: depression beginning early, especially before age 25; recurrent, high-frequency depressive episodes; psychotic features; postpartum mood episodes; a strong family history of bipolar disorder; and antidepressant-associated mood switching or activation —
Screening instruments — useful, and not diagnostic These tools "demonstrate moderate sensitivity," but "their specificity is limited," so they are to be used "as adjuncts rather than diagnostic instruments, with positive results prompting structured clinical interviews." A negative screen does not exclude bipolar disorder; the Hypomania Checklist’s 57% specificity means a positive one is often wrong too Mood Disorders Questionnaire — sensitivity 80%, specificity 70%. Hypomania Checklist 32 — sensitivity 82%, specificity 57%. Also named: the Young Mania Rating Scale (11 items on the past 24 hours, with a parent version) and the Altman Self-Rating Mania Scale —
Lithium serum level — the target range and how to draw it UNITS FIRST, because this page moves between two of them and the comparison is the whole point. Lithium is monovalent, so 1 mEq/L and 1 mmol/L are the same number — the FDA label writes the toxic threshold as "≥1.5 mEq/L" while the toxicity literature writes the identical threshold as 1.5 mmol/L. Read every figure below in whichever unit it is printed and compare them directly. The range is FDA product labeling, cited directly: "Acute Manic or Mixed Episodes (patients 7 years and older): Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L"; "Maintenance Treatment for Bipolar I Disorder (patients 7 years and older): Titrate to serum lithium concentrations 0.8 to 1 mEq/L." The label states the squeeze outright: "The toxic concentrations for lithium (≥1.5 mEq/L) are close to the therapeutic range (0.8 to 1.2mEq/L)." And the label is explicit that the number is not the whole answer: "TOTAL RELIANCE MUST NOT BE PLACED ON SERUM CONCENTRATIONS ALONE. Accurate patient evaluation requires BOTH clinical and laboratory analysis." The boxed warning frames the whole problem: "lithium toxicity is closely related to serum lithium levels and can occur at doses close to therapeutic levels. Before initiating therapy, ensure that lithium levels will be able to be measured promptly and accurately" 0.8 to 1.2 mEq/L for acute goals; 0.8 to 1.0 mEq/L for maintenance goals. Draw the sample "immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 12 hours after the previous dose)." Beyond routine maintenance monitoring, re-check "after any change in dosage, concurrent medication (e.g., DIURETICS, NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, RENIN-ANGIOTENSIN SYSTEM ANTAGONISTS, or METRONIDAZOLE), marked increase or decrease in routinely performed strenuous physical activity (such as an exercise program) and in the event of a concomitant disease" FDA-approved prescribing information for lithium carbonate (current label) Lithium is not normally present; the therapeutic window is narrow and toxicity begins close to it
Baseline and ongoing tests before and during lithium Each has a reason. Renal function because lithium is cleared entirely by the kidney; thyroid because lithium accumulates in the thyroid gland, inhibiting synthesis and release, potentially causing hypothyroidism; calcium because prolonged use is associated with persistent hyperparathyroidism and hypercalcemia; weight because lithium causes weight gain. Nutrition and hydration labs — sodium, hematocrit, albumin, prealbumin — are added in mania because intake collapses Before the first dose: kidney and thyroid function tests and a recorded weight. There is a cardiac reason to think about an ECG as well — lithium "can cause abnormal electrocardiographic (ECG) findings and risk of sudden death" — but no source behind this page sets a baseline-ECG age rule, so none is printed. During therapy: those tests once or twice annually, plus urinalysis, BUN and creatinine, thyroid studies and calcium —
Interpreting a lithium level in suspected toxicity The number is the weakest piece of evidence you have. Levels "may not correlate with severity, particularly in cases of chronic toxicity"; acute toxicity is often asymptomatic at high concentrations while chronic toxicity causes neurologic impairment at relatively lower concentrations; symptoms may worsen as the level falls, because distribution into the central nervous system is slow; and samples collected in lithium heparin tubes read falsely high. Interpret levels "in conjunction with clinical findings" Clinical findings of toxicity "commonly occur at lithium concentrations greater than 1.5 mmol/L," traditionally categorised as mild 1.5–2.5, moderate 2.5–3.5, and severe above 3.5 mmol/L. A second source names above 2.5 mEq/L as a medical emergency even in an asymptomatic client EXTRIP-aligned bands, as reported by StatPearls —

Complications

Warning: Lithium toxicity Report immediately
"Most cases of lithium toxicity are preventable and occur in individuals receiving chronic lithium therapy." Prevention "relies on careful monitoring, patient education, and recognition of factors that increase the risk of toxicity." In one cohort 7% had at least one level above 1.5 mmol/L; among those with toxicity, 34% required intensive care and 13% required hemodialysis.
There is no antidote. Mild toxicity may need only discontinuation; moderate toxicity needs supportive care and intravenous isotonic fluid to promote renal clearance, watching volume status and sodium to avoid hypernatremia. Lithium does not bind to activated charcoal. Dialysis is recommended when renal function is impaired with a level above 4.0 mmol/L, or when decreased consciousness, seizures or life-threatening dysrhythmias are present regardless of the level; it is suggested above 5.0 mmol/L, with significant confusion, or when the expected time to fall below 1.0 mmol/L exceeds 36 hours. Hemodialysis is preferred, and repeated sessions may be needed because of rebound after dialysis. Mortality is now under 1%, but SILENT — irreversible lithium-effectuated neurotoxicity — can leave permanent cerebellar dysfunction with ataxia, dysarthria and dysmetria even without toxic levels.
Warning: Suicide Report immediately
Bipolar disorder carries "among the highest suicide risks of all psychiatric disorders," with lifetime suicide attempt rates estimated between 25% and 50%. The mortality ratio from suicide is 20 times above the general population rate and exceeds rates for other mental health disorders.
The phase is the cue: "most suicide attempts and completed suicides occur during depressive or mixed episodes rather than during manic episodes," which is why suicide assessment "should be performed at initial evaluation and repeated throughout treatment." Sourced risk factors include prior attempts, bipolar depression, mixed features, rapid cycling, substance use and anxiety disorders, psychotic symptoms, early onset and recent hospitalization, and comorbid metabolic syndrome and borderline personality disorder both carry increased suicidality. Lithium is the one mood stabiliser "consistently associated with reduced suicide mortality," which is a reason to persist with it. Assessment technique and safety planning belong to the Depression page.
Warning: Relapse after stopping treatment Hold & notify
"Because bipolar disorder is highly recurrent, maintenance therapy is recommended after virtually all manic episodes and most depressive episodes," and it is "generally continuous rather than episodic." The trap is built into the illness: "between episodes, many people with bipolar disorder are free of mood disruption" — so the medication looks unnecessary exactly when it is working.
The second trap is stopping treatment when a mood lifts or side effects bother — patients are taught to "Take all medicines as directed" and to "Avoid stopping medication without talking to your health care provider first." Patient compliance is low and relapses are common. The sourced countermeasures are continuous rather than episodic treatment, including family members or caregivers in education so they can help recognise early symptoms, and teaching the warning sign by name: decreased need for sleep.
Caution: Premature death and metabolic burden
Life expectancy is reduced by approximately 8 to 15 years compared with the general population, with cardiovascular disease the leading cause of excess natural mortality and cardiovascular mortality about 2-fold higher. One-third to one-half meet criteria for metabolic syndrome, and type 2 diabetes occurs at about 2 to 3 times the general-population rate.
And the scale, with its owner attached, because an unowned single percentage is the wrong way to teach this: globally, bipolar disorder "affects approximately 0.5% to 2.4% of the population, depending on diagnostic criteria and the breadth of the bipolar spectrum considered"; in the United States, NIMH data give a 12-month prevalence of 2.8% and a lifetime prevalence of about 4.4%; and an older reference chapter gives "about 4 percent" for lifetime prevalence. Quote whichever you use with its source, and do not average them. Metabolic syndrome in bipolar disorder is associated with greater illness severity, more frequent recurrence, more hospitalization, reduced treatment response and increased suicidality, so it is not a side issue. Bipolar disorder "remains among the leading causes of disability worldwide."
Caution: The wreckage a manic episode leaves behind
"The sequelae from a manic episode can be detrimental. Those suffering from mania often act with impropriety, ruining reputations and careers. More consequential complications include physical harm to others and self."
Psychiatric comorbidity affects the majority of patients: anxiety disorders are the most common, substance use disorders occur in about one-third to one-half, borderline personality disorder is the most frequently identified personality disorder, and binge-eating disorder and bulimia nervosa are increased — each linked to more complex illness and poorer outcomes, and several to higher suicidality. The nursing framing for the maintenance phase is the useful one: "interpersonal, occupational, educational, and financial consequences may occur. Clients need support as they recover from acute illness and repair their lives."

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Mood Stabilizers (Lithium) First-line
Nervous · lithium carbonate

A first-line treatment, and the only agent here with an antisuicidal property. Lithium is on the first-line list for acute mania in the CANMAT/ISBD and WFSBP guidelines, as reported by StatPearls, and it carries something none of the others do: it "remains the best-supported maintenance treatment," and it remains "the only mood stabilizer consistently associated with reduced suicide mortality across multiple studies"; the nursing text adds that it "possesses unique antisuicidal properties that sets it apart from antidepressants." That property is the disorder-side reason lithium survives its own toxicity profile. Expect 1 to 3 weeks for symptom relief — lithium "may reduce symptoms within one to three weeks" — and expect that a full response is not guaranteed. The therapeutic range is 0.8 to 1.2 mEq/L for acute goals and 0.8 to 1.0 mEq/L for maintenance, per the current FDA label (an older legacy label still in circulation prints a 0.6 floor; the current labeling supersedes it), drawn immediately before the next dose, about 12 hours after the previous one, and re-checked after any dose change, any new interacting medicine, a marked change in strenuous exercise, or any intercurrent illness. Why the safety rules are so strict is pharmacokinetic, not cautionary: lithium is neither protein bound nor metabolized, the proximal tubule reabsorbs 80% of it through sodium transport pathways, and "even minor changes in volume status, renal perfusion, or sodium balance can produce clinically significant changes in serum lithium concentrations." Toxicity most commonly results from reduced renal clearance rather than excessive ingestion, and chronic toxicity is the commonest pattern and is usually unintentional. One labelled interaction runs the other way and is worth a line precisely because it surprises people: “Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations,” and it instructs: “Monitor serum lithium concentration more frequently during SGLT2 inhibitor initiation and dosage changes.” The label also names a “marked increase or decrease in routinely performed strenuous physical activity (such as an exercise program)” among the situations calling for more frequent levels — primary confirmation of the sweating-and-exercise teaching below. Distinguish the expected from the dangerous: a fine hand tremor, polyuria and mild thirst may persist throughout treatment — a coarse tremor, slurred speech, unsteadiness or confusion is toxicity. Long-term effects that are not toxicity include nephrogenic diabetes insipidus, hypothyroidism from thyroid accumulation, and hyperparathyroidism with hypercalcemia. Contraindicated in renal or cardiovascular disease, severe dehydration or sodium depletion, and in patients receiving diuretics; avoided below a creatinine clearance of 30 mL/min, especially where a low-sodium diet is required. In pregnancy, first-trimester exposure raises the risk of cardiac malformation, particularly Ebstein anomaly; lactation is not advisable. The class page owns the dosing detail; this page teaches why hydration and sodium are drug-safety issues.
Anticonvulsants First-line
Nervous · phenytoin

A first-line mood stabiliser for mania — with one boxed fetal-risk restriction and one common error. On the CANMAT/ISBD and WFSBP first-line lists for acute mania, as reported by StatPearls, divalproex/valproate stands alongside lithium, and "lithium or valproate plus an antipsychotic" is the usual combination for severe mania, psychosis or an inadequate response. StatPearls notes that "differences exist among guidelines," so these are the carrier’s synthesis, not one society’s rule. The mechanistic reason anticonvulsants belong on a mood-disorder drug list is sourced: "newer research indicates altered intracellular calcium signaling occurs in people with bipolar disorders, and antiseizure medications can provide effective treatment." Carbamazepine sits in the same historical group. The pregnancy rule, from the FDA label: "valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable," because in-utero exposure causes neural tube defects, other major malformations and decreased IQ; StatPearls adds that it "should generally be avoided in women of childbearing potential unless no suitable alternatives exist and effective contraception is ensured." Never present "lithium or valproate" as an even choice for a patient of childbearing potential without that restriction attached. The common error is lamotrigine. It belongs on the depressive side of bipolar disorder — named in combination with lithium for acute bipolar depression, and among the mood stabilisers to which an antidepressant may be added — but a meta-analysis found that "gabapentin, lamotrigine, and topiramate showed no difference when compared to placebo for treating mania." Lamotrigine does not treat acute mania, and gabapentin and topiramate have no sourced role in bipolar disorder at all. On comparative efficacy in acute mania, the sourced ranking is honest about hierarchy: atypical antipsychotics outperformed mood stabilisers for the acute episode, with valproic acid, carbamazepine and ziprasidone more effective than placebo but less so than risperidone, olanzapine, haloperidol, lithium, quetiapine and aripiprazole.
Antipsychotics First-line
Nervous · haloperidol

The class that covers both poles, which is why it is a maintenance mainstay. On the CANMAT/ISBD and WFSBP first-line lists for acute mania, as reported by StatPearls, the second-generation antipsychotics named are quetiapine, risperidone, aripiprazole, asenapine, cariprazine, olanzapine and paliperidone, alongside lithium and valproate, and a large meta-analysis found atypical antipsychotics more effective than mood stabilisers for acute mania — "but not necessarily for maintenance." Two are also first-line for acute bipolar depression — quetiapine and lurasidone (alone or added to lithium or divalproex), with cariprazine also listed — while olanzapine-fluoxetine "remains an evidence-supported option but is often reserved because of metabolic adverse effects." In maintenance, quetiapine, aripiprazole, olanzapine and long-acting injectable risperidone are among the evidence-supported options, with lithium the best-supported. (Any valproate/divalproex option carries the pregnancy restriction on the valproate row.) For escalating agitation in an acute manic episode, the nursing text describes "immediate administration of a prescribed antipsychotic and/or benzodiazepine," noting that an injectable combination of haloperidol and lorazepam is commonly used for rapid onset of action, and "the nurse must monitor for respiratory depression, hypotension, and oversedation" afterwards. Clozapine and electroconvulsive therapy "have shown many benefits for treatment-resistant mania but are less commonly used." One disorder-side interaction is worth carrying: neuroleptic malignant syndrome may be caused by low-potency and atypical antipsychotics, antiemetics, tricyclic antidepressants and lithium, and concurrent use of multiple neuroleptic agents or lithium increases the risk — so a bipolar patient on lithium plus an antipsychotic carries both risks at once. The rest of the antipsychotic adverse-effect burden — extrapyramidal symptoms, tardive dyskinesia, metabolic syndrome, prolactin elevation, QTc prolongation and the dementia-related-psychosis boxed warning — is taught on the Schizophrenia page and the class page, and is not re-derived here.
SSRIs
Nervous · sertraline

Mostly a warning, and the warning is the teaching. Per the guidelines as reported by StatPearls, "antidepressant monotherapy is not recommended for bipolar I depression and should generally be avoided in patients with mixed features, rapid cycling, or previous antidepressant-induced switching," because antidepressant monotherapy "can precipitate mania, hypomania, or rapid cycling." What is permitted is combined use: "when antidepressants are used, they should typically be combined with a mood stabilizer or antipsychotic and closely monitored" — the nursing version is that an antidepressant may treat a bipolar depressive episode "in combination with a mood stabilizer and/or an antipsychotic to prevent precipitating a manic episode." In acute mania, antidepressants and other activating agents are discontinued when clinically appropriate. NIMH states antidepressants "are not used alone because they can trigger a manic episode or rapid cycling." Fluoxetine’s named bipolar role is the olanzapine-fluoxetine combination, which "remains an evidence-supported option but is often reserved because of metabolic adverse effects" — never an SSRI alone. The diagnostic corollary is worth more than the prescribing rule: mood switching or activation on an antidepressant is one of the features that should raise suspicion of bipolar disorder in a patient being treated for depression. The Depression page owns the monitoring instruction to report new increased activity and talking when an antidepressant is started or changed, and it owns the FDA antidepressant boxed warning.

Beyond medications

  • Psychotherapy works as an add-on and never as a substitute. The sourced limit is explicit: "psychotherapy should not be considered a substitute for pharmacotherapy in bipolar I disorder, but is recommended as an adjunctive treatment throughout the course of illness." Named modalities include psychoeducation, CBT, family-focused therapy, interpersonal and social rhythm therapy and relapse-prevention programs, with dialectical behavior therapy also named in the nursing text.
  • Two therapies are bipolar-specific and both are about structure. Interpersonal and social rhythm therapy "emphasizes the importance of establishing stable daily routines such as sleeping, waking up, working, and eating meals" — it is the therapeutic expression of the sleep finding, because routine protects sleep and sleep protects mood. Family-focused therapy "focuses on psychoeducation, communication enhancement training, and problem-solving skills."
  • Psychoeducation has a defined curriculum. Delivered individually or in a group, to patients and family members, it "may include teaching to detect and manage prodromes of depression and mania, enhance medication adherence, and improve lifestyle choices. Patients are encouraged to avoid stimulants, eg, caffeine, minimize alcohol consumption, exercise regularly, and practice appropriate sleep hygiene."
  • Electroconvulsive therapy has sourced indications at both poles: in mania, treatment-resistant mania, severe psychotic mania, catatonia, and situations needing rapid improvement — including pregnancy when medication risks are substantial; in depression, severe, psychotic or treatment-resistant bipolar depression, catatonia, or acute suicidal risk. The nursing text adds the practical case — ECT "can also be effective when a rapid response is needed, as in the case of suicide risk or catatonia." Repetitive transcranial magnetic stimulation is a separate option for depressive episodes and "does not require general anesthesia."
  • Lifestyle measures, each with its sourced rationale. Regular aerobic exercise — jogging, brisk walking, swimming, cycling — "helps with depression and anxiety, promotes better sleep, and is healthy for the heart and brain." A balanced diet such as the Mediterranean diet "can positively impact mood and metabolic health," which matters given that a third of patients meet criteria for metabolic syndrome. Maintain a regular sleep schedule, practise mindfulness or meditation, avoid alcohol, tobacco and recreational drugs, and build and maintain strong social connections.
  • Mood charting turns a fluctuating illness into data. "Keeping a life chart that records daily mood symptoms, treatments, sleep patterns, and life events can help clients and health care providers track and treat bipolar disorder over time." Smartphone apps let patients share self-reports, self-ratings and activity data directly with the team.
  • The therapeutic alliance has measured effects. Providers are encouraged to "maximize the therapeutic alliance, convey empathy, allow patients to participate in treatment decisions, and consistently monitor symptoms, which have been shown to reduce suicidal ideation, improve treatment outcomes, and increase patient satisfaction with care." Care is coordinated across the interprofessional team, with shared decision-making, supportive monitoring technology, coordinated communication and relapse-prevention strategies named as ways to reduce adverse events and prevent complications.
  • Case management and community resources. Patients "may also benefit from case management or care coordination services to help connect them to community-based resources, such as support groups, mental health centers, and substance use treatment programs." Named organisations include NAMI and the Depression and Bipolar Support Alliance; outpatient services "provide structure and decrease social isolation." Short-term benzodiazepines may be used in acute mania for agitation, insomnia or severe behavioural dysregulation — a plain-text note here, since sleep restoration is itself a therapeutic target in mania.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Open every bipolar assessment with two questions: is this person a danger to self or others, and are they physiologically stable?
Why: The sourced pair. On danger: the client may have suicidal or homicidal ideation, and "poor impulse control may result in harm to self or others. Assess the need for protection from uninhibited behaviors. For example, external controls may be needed to protect the client from consequences such as bankruptcy." On stability: obtain vital signs and labs including electrolytes, because "the client may not eat or sleep for days at a time with potential physiological consequences."
Interview family or significant others, and treat the patient’s own account of past highs as incomplete rather than as the record.
Why: "Clients with mania, hypomania, or psychosis often have poor insight and may have difficulty providing an accurate history," and in mania "the problem is mainly noticed by others." The diagnosis itself depends on episodes the patient may not recognise as abnormal — and the five-to-ten-year diagnostic delay is built on exactly that gap.
Track sleep as a vital sign: hours slept, and whether the patient feels rested.
Why: Reduced need for sleep is a criterion symptom, not insomnia, and it is the named early-warning sign for a manic relapse. The acute-phase nursing plan reinforces a minimum of four to six hours of sleep per night, and stabilising sleep and wake routines is a treatment in its own right.
Draw lithium levels "immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 12 hours after the previous dose)," and check kidney and thyroid function before the first dose ever given, with a recorded weight. Ask about cardiac history and about fainting or light-headedness, because lithium "can cause abnormal electrocardiographic (ECG) findings and risk of sudden death," and clients "should be advised to seek immediate emergency assistance" for those symptoms.
Why: Level timing changes the number, so a level drawn at the wrong interval misleads the prescriber. The baseline tests exist because lithium is cleared entirely by the kidney, accumulates in the thyroid and inhibits hormone synthesis, and causes weight gain. Repeat these once or twice annually, along with calcium, because prolonged use is associated with hyperparathyroidism and hypercalcemia.
Do not let the lithium level reassure you when the patient looks unwell.
Why: Levels "may not correlate with severity, particularly in cases of chronic toxicity"; acute toxicity is often asymptomatic at high concentrations; chronic toxicity causes neurologic impairment at relatively lower concentrations; symptoms may worsen as the level falls because distribution into the central nervous system is slow; and a sample drawn into a lithium heparin tube reads falsely high. The rule that outranks all of it: vomiting, confusion or cerebellar signs in anyone with access to lithium is toxicity until proven otherwise.
In mania, add the nutrition and hydration labs — serum sodium, hematocrit, albumin and prealbumin.
Why: These are not routine screening here; they are the consequence of not eating for days. The sourced list names them as parameters that "can become impaired during manic episodes due to poor intake," and the acute goals include stable cardiac status, good hydration, sufficient sleep and rest, and intact tissue integrity.
Interventions & safety
Run the manic safety bundle: reduce stimuli with a calming milieu, redirect firmly, offer finger foods with hydration, schedule rest periods twice a day, avoid large group activities, and use short one-to-one contacts.
Why: Every element of that bundle comes from one sourced care-plan sentence, so it can be taught as written. The reasoning behind it is in the acute-phase focus: "managing medications, decreasing physical activity, increasing food and fluid intake, reinforcing a minimum of four to six hours of sleep per night, and ensuring self-care needs are met." Finger foods work because a patient who cannot sit still can eat while moving.
Do not argue with grandiose ideas. Acknowledge the emotion behind the belief and redirect without confrontation.
Why: "Debating delusional or inflated beliefs can increase defensiveness and agitation," and these patients "are highly unlikely to respond to outsiders’ views." The sourced technique is to validate the emotion without reinforcing the behavior — say "it sounds like you’re feeling really energized today" rather than "wow, you’ve done so much!" — then reinforce reality gently and consistently.
Use short, clear, concrete statements, keep a calm non-reactive demeanor, and set firm but respectful limits on behavior.
Why: Each is sourced with its reason: short statements because "during mania, attention span and focus are impaired"; a calm manner because it "provides a model of self-regulation"; and firm limits because clients may become intrusive, impulsive or overstimulated. When the patient changes topic rapidly, redirect explicitly — "earlier you mentioned you were having problems sleeping – let’s talk more about that."
Attempt de-escalation at the earliest signs of escalating agitation, and treat seclusion or restraint as a last resort under policy and ANA guidance.
Why: "De-escalation techniques should be attempted at early signs of escalating agitation to avoid the need for seclusion or restraints." They may become necessary if clients "pose an immediate risk of injury to themselves or others," but "most state laws prevent the use of unnecessary restraint or seclusion, so their use is associated with complex ethical, legal, and therapeutic issues."
After giving injectable haloperidol with lorazepam for rapid control of agitation, monitor for respiratory depression, hypotension and oversedation.
Why: This combination is named as commonly used for rapid onset in an escalating manic episode, and the monitoring requirement is stated with it. The bipolar patient is often simultaneously on lithium, which itself increases neuroleptic malignant syndrome risk alongside an antipsychotic — so a rising temperature with rigidity after this combination is not a minor finding.
When a patient on lithium develops vomiting, diarrhea, fever or heavy sweating, treat it as a lithium problem, not just an illness.
Why: Volume and sodium depletion increase tubular lithium reabsorption and decrease excretion, so the level climbs with no change in dose. The FDA label states the mechanism and the teaching together: "DEHYDRATION from protracted SWEATING, DIARRHEA, or ELEVATED TEMPERATURES FROM INFECTION increases risk of hyponatremia and lithium toxicity. Educate patients on maintaining a NORMAL DIET WITH SALT and STAYING HYDRATED." Hyponatraemia and lithium toxicity are the same event described twice, which is why the sick-day rule is a drug-safety rule. Management of established toxicity is withholding the drug and giving intravenous isotonic fluid, watching sodium to avoid hypernatremia — there is no antidote, and activated charcoal does not bind lithium.
Wait until the mania begins to settle before doing the teaching.
Why: The sourced timing rule: "the client may be resistant to teaching during the acute phase of a manic episode, so it is beneficial to wait until manic symptoms begin to resolve." Attention span and focus are impaired in mania, so education delivered at the peak is education wasted — and it costs the therapeutic relationship the patient will need later.
Patient & family teaching
Teach consistent sodium and fluid intake — not restriction, and not loading.
Why: The sourced word is consistency in both directions: "drastic reduction in sodium can lead to lithium toxicity, and a drastic increase in sodium intake can lead to sub-therapeutic lithium." The FDA label puts it as patient teaching: "educate patients on maintaining a NORMAL DIET WITH SALT and STAYING HYDRATED," with particular care during protracted sweating, diarrhoea, or a fever from infection — and a marked increase or decrease in strenuous physical activity is itself a reason to re-check the level.
Give the report-immediately list for lithium in the patient’s own words, and the emergency list separately.
Why: Notify the provider for diarrhea, vomiting, drowsiness, muscular weakness, lack of coordination, ringing in the ears, or large amounts of dilute urine — the second source adds nausea, tremor, confusion and worsening coordination. Seek immediate emergency assistance for fainting, light-headedness, abnormal heartbeats or shortness of breath. Also teach that a fine tremor is expected while a coarse tremor is not.
Teach that NSAIDs, diuretics and ACE inhibitors change lithium levels, and that every clinician — including the dentist — must be told about the lithium.
Why: Patients are educated "about medications that affect renal function or sodium balance," and specifically advised to inform all healthcare professionals, including dentists and other specialists, and to consult their clinician before starting any new prescription or over-the-counter medication. An over-the-counter anti-inflammatory bought for a headache is a genuine route to toxicity.
Name the relapse warning sign explicitly: decreased need for sleep.
Why: Patients are taught to "learn to recognize mood swings and warning signs for manic episodes such as decreased need for sleep." The corollary lifestyle instruction follows from it: "maintain a structure for daily activities; keep a routine for eating, getting enough sleep, and exercising."
Address head-on the commonest reason people stop: feeling well between episodes.
Why: "Between episodes, many people with bipolar disorder are free of mood disruption," and feeling well is exactly when stopping is most tempting. The sourced counter-message is plain: "Avoid stopping medication without talking to your health care provider first," and the lithium Medication Guide says "Do not stop taking Lithium Carbonate suddenly without talking to your healthcare provider." Include family members or caregivers in the teaching so they can help recognise early symptoms and support monitoring.
Warn against driving or operating heavy machinery when first starting lithium.
Why: It "can impair mental alertness." This is a short-term, start-of-treatment instruction that is easy to omit and easy for a patient to discover the hard way.
Teach the rest of the sourced self-management block: avoid alcohol and illicit drugs, keep appointments, use stress management and relaxation, join a support group, and be patient because improvement takes time.
Why: Alcohol and substance use are both triggers and mimics, and "self-medication through alcohol or other substances often complicates recovery." Individuals are "often ambivalent about treatment," but bipolar disorders "typically require medications to be taken over long periods of time or for a lifetime to prevent relapse" — which is why "ask for help when experiencing barriers or challenges" is on the teaching list beside the medication instructions.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    Four cue sets arrive at once and they all point the same way. The symptoms are the neurologic rung of the lithium toxicity ladder — drowsiness, coarse tremor, slurred speech and ataxia are named together, and tinnitus with unsteadiness belongs to the higher-level nursing list. The exposure is two days of vomiting and diarrhea with almost no intake, which is volume and sodium depletion. The drug list contains a new NSAID, started yesterday, which is explicitly on the interaction list alongside thiazides, ACE inhibitors and angiotensin receptor blockers. And the last level was reassuringly normal two weeks ago, which tells you nothing about today. Note the one thing that is not a cue: he has not taken extra lithium. He is compliant, and that is precisely the point — chronic toxicity "is the most common pattern and is usually unintentional."

  2. 2
    Analyze cues

    The mechanism is one sentence. Lithium is cleared almost entirely by the kidney, and the proximal tubule reabsorbs 80% of it through sodium transport pathways. Vomiting, diarrhea and poor intake deplete volume and sodium; the kidney responds by conserving sodium; because it cannot tell lithium and sodium apart, it conserves lithium too. The NSAID reduces renal perfusion and compounds it. The serum level has been climbing for two days on an unchanged dose. The second piece of reasoning is the one that prevents a fatal reassurance: this is chronic toxicity, which is "more often associated with neurologic symptoms even at relatively lower lithium concentrations," and "because lithium distribution into the central nervous system occurs slowly, neurologic symptoms may develop even as serum lithium concentrations decline." So a level that comes back at 1.8 rather than 3.5 does not mean he is fine. The governing rule is clinical: "any patient who is prescribed or has access to lithium and develops vomiting, confusion, or cerebellar signs should be presumed to have lithium toxicity until proven otherwise."

  3. 3
    Prioritize

    First, on this telephone call, tell the mother to hold the next lithium dose and stop the ibuprofen. Both are actively raising the level right now, and the instruction costs nothing and takes seconds — doing it before anything else removes two ongoing insults while the rest is being arranged. Second, get him assessed in person today — this is not a telephone-advice problem. He has cerebellar signs and altered alertness, and hospital admission "should be considered for individuals with clinical signs and symptoms of toxicity." Third, the tests that will guide management — serum lithium, renal function, and electrolytes including sodium. Fourth, the fluid problem, which is both the cause and part of the treatment: intravenous isotonic fluid promotes renal lithium clearance. Fifth, the question nobody should skip — whether this ingestion was unintentional, since "patients with intentional lithium overdose should undergo evaluation and treatment of acute suicidality." His story is a straightforward gastroenteritis, but the question gets asked.

  4. 4
    Generate solutions

    Anticipate withholding the lithium and giving intravenous isotonic fluid, with careful monitoring of volume status and serum sodium "to prevent hypernatremia." Anticipate serial lithium levels, because a single value can be misleading and "initial concentrations may not represent peak concentrations." Know what will not be used: there is no antidote, and lithium does not bind to activated charcoal — charcoal is given only if a co-ingestion is suspected. Know when dialysis enters the conversation: it is recommended if renal function is impaired with a level above 4.0 mmol/L, or if there is decreased consciousness, seizures or life-threatening dysrhythmia regardless of the level; and suggested above 5.0 mmol/L, with significant confusion, or if the expected time to fall below 1.0 mmol/L exceeds 36 hours. Hemodialysis is preferred, and repeated sessions may be needed because of rebound. Plan the discharge teaching that clearly did not land the first time: consistent sodium and fluids, the sick-day rule, and no over-the-counter NSAIDs without checking.

  5. 5
    Take action

    Tell the mother, in plain words, to hold the lithium, stop the ibuprofen, and bring him in now — and to call an ambulance instead if he becomes confused, has a seizure, faints, or his heartbeat feels abnormal. Escalate with an SBAR: "22-year-old man on maintenance lithium since a first manic episode six weeks ago, level 0.9 two weeks ago. Two days of vomiting and diarrhea with almost no intake, and he started over-the-counter ibuprofen yesterday. He now has a coarse tremor, slurred speech, ataxia, drowsiness and tinnitus. I am treating this as lithium toxicity until proven otherwise — volume and sodium depletion plus an NSAID on a drug the proximal tubule reabsorbs with sodium. Lithium held, ibuprofen stopped, coming in now. Requesting lithium level, renal function and electrolytes, and IV isotonic fluid." Three traps to avoid. Waiting for the level before acting — the clinical rule outranks the number. Treating a level of 1.8 as reassuring — chronic toxicity causes neurologic harm at lower concentrations and can worsen as the level falls. And reading this as non-adherence: he did everything he was told, and the system failed to teach him the sick-day rule.

  6. 6
    Evaluate

    Success over the next 24 to 72 hours: vomiting controlled, volume restored, the level falling, and — the finding that actually matters — the tremor, speech and gait returning to baseline, since "most signs and symptoms do resolve as serum lithium concentrations decline." Discharge may be considered once clinical improvement has occurred and levels remain below 1.5 mmol/L, "a process that may require several days." The sequela to watch for and name: SILENT — irreversible lithium-effectuated neurotoxicity — leaves permanent cerebellar dysfunction with ataxia, dysarthria and dysmetria, and can occur even without toxic levels. Over the following weeks: rebuild the teaching that failed. Consistent sodium and fluids; a written sick-day rule for vomiting, diarrhea, fever, hot weather and strenuous exercise; tell every clinician including the dentist about the lithium; no new over-the-counter medicine without checking; and the report-immediately list. Restore the monitoring schedule, because "adherence to recommended laboratory monitoring is essential during lithium therapy." And keep the lithium if it can be kept — it is the one agent with sourced antisuicidal properties.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Outpatient psychiatry clinic, telephone triage · 1420, six weeks after discharge

A 22-year-old man was discharged six weeks ago after a first manic episode: six days of sleeping about three hours a night and feeling rested, speech nobody could interrupt, $9,000 spent on equipment for a business he founded that week, and a belief that he had been recruited by a government agency. He was admitted, started on lithium, and left on a stable dose with a level of 0.9 mEq/L. His mother calls the clinic because he has had two days of vomiting and diarrhea from a stomach bug and now "cannot walk straight."

Reported by mother — vomiting and watery diarrhea for 2 days, poor oral intake, has kept taking his lithium exactly as prescribed
Now — unsteady on his feet, speech slurred, hands shaking coarsely, drowsy but rousable, complaining of ringing in his ears
Last clinic labs, 2 weeks ago — lithium 0.9 mEq/L · creatinine and TSH normal · weight stable
Medications — lithium as prescribed · ibuprofen 400 mg three times daily started yesterday for abdominal cramping, bought over the counter
Mother’s note — "He is drinking almost nothing and he has not eaten since Tuesday."
Q1 Select all that apply
Which findings indicate probable lithium toxicity? Select all that apply.
  1. A. Coarse tremor of the hands with slurred speech and an unsteady gait
  2. B. Two days of vomiting and diarrhea with almost no oral intake
  3. C. Ibuprofen 400 mg three times daily started yesterday
  4. D. Ringing in the ears with drowsiness
  5. E. A fine hand tremor present since the drug was started six weeks ago
Reveal answer & rationale
Answer: A, B, C, D
The coarse tremor with slurred speech and ataxia (A) is the neurologic rung of the toxicity ladder, and the neurologic system is the most commonly affected, especially in chronic toxicity. The vomiting and diarrhea with poor intake (B) is the mechanism: volume and sodium depletion increase renal lithium reabsorption and decrease excretion. The NSAID (C) is explicitly on the interaction list with thiazides, ACE inhibitors and angiotensin receptor blockers. Tinnitus with drowsiness (D) belongs to the higher-level nursing list — "giddiness, ataxia, blurred vision, tinnitus, and a large output of dilute urine." A fine hand tremor (E) is the one item that is expected: "fine hand tremor, polyuria, and mild thirst may persist throughout treatment." Tremor quality is the discriminator.
Q2 Multiple choice
The lithium level returns at 1.8 mEq/L. The nurse should understand that:
  1. A. This level is only mildly elevated, so the symptoms must have another cause
  2. B. The level must be interpreted alongside the clinical findings, because chronic toxicity causes neurologic impairment at relatively lower concentrations
  3. C. Dialysis is indicated immediately at any level above 1.5 mEq/L
  4. D. The symptoms will resolve as soon as the level falls below 1.5 mEq/L
Reveal answer & rationale
Answer: B
Levels must be read with the clinical picture (B): they "may not correlate with severity, particularly in cases of chronic toxicity," and chronic and acute-on-chronic toxicity are "more often associated with neurologic symptoms even at relatively lower lithium concentrations." Dismissing the symptoms (A) is the exact error the sources warn against, and it ignores that acute toxicity can be asymptomatic at high levels while chronic toxicity is symptomatic at low ones. Immediate dialysis (C) misstates the thresholds — it is recommended with impaired renal function above 4.0 mmol/L (the same number as 4.0 mEq/L) or with decreased consciousness, seizures or life-threatening dysrhythmias regardless of level. Expecting immediate resolution (D) ignores that "because lithium distribution into the central nervous system occurs slowly, neurologic symptoms may develop even as serum lithium concentrations decline."
Q3 Put in order
Put the nurse’s telephone-triage actions in order:
  1. A. Arrange for him to be seen and assessed in person today
  2. B. Instruct the mother to hold the next lithium dose and stop the ibuprofen
  3. C. Request a serum lithium level, renal function and electrolytes
  4. D. Plan the sick-day teaching he will need before discharge
Reveal answer & rationale
Correct order: B → A → C → D
Holding the lithium and stopping the NSAID (B) comes first because both are actively raising the level right now, and it costs nothing and takes seconds over the telephone. Arranging in-person assessment (A) follows immediately: he has cerebellar signs and altered alertness, and admission "should be considered for individuals with clinical signs and symptoms of toxicity." The laboratory work (C) follows because it guides management — but it does not gate the first two actions, since "vomiting, confusion, or cerebellar signs" in anyone with access to lithium is presumed toxicity until proven otherwise. Sick-day teaching (D) is genuinely essential, since this episode happened because it was missing, but it belongs to the recovery phase, not to the triage call.
Q4 Multiple choice
A different patient with bipolar I disorder presents with a two-week depressive episode. Which prescription would the nurse question?
  1. A. Quetiapine as monotherapy
  2. B. Sertraline as monotherapy
  3. C. Lithium plus lamotrigine
  4. D. Lurasidone plus lithium
Reveal answer & rationale
Answer: B
An SSRI alone (B) is the one to question: "antidepressant monotherapy is not recommended for bipolar I depression," because it can precipitate mania, hypomania or rapid cycling; when antidepressants are used they are combined with a mood stabiliser or antipsychotic. Quetiapine (A) is on the first-line list for acute bipolar depression, alongside lurasidone, lithium and lamotrigine. Lithium plus lamotrigine (C) is a named combination for acute bipolar depression — and note that lamotrigine belongs on the depressive side, since "gabapentin, lamotrigine, and topiramate showed no difference when compared to placebo for treating mania." Lurasidone plus lithium (D) is also a named combination.
Q5 Multiple choice
A 26-year-old woman with a first manic episode is to be started on a mood stabiliser. Which additional information most changes the choice of agent?
  1. A. She drinks two cups of coffee daily
  2. B. She is of childbearing potential
  3. C. She reports a family history of hypertension
  4. D. She exercises three times per week
Reveal answer & rationale
Answer: B
Childbearing potential (B) triggers the key restriction: the FDA label says "valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable," and StatPearls says it "should generally be avoided in women of childbearing potential unless no suitable alternatives exist and effective contraception is ensured." Since valproate is otherwise on the first-line list alongside lithium, this single fact effectively removes one of the two standard mood-stabiliser choices. Lithium has its own pregnancy issue — first-trimester exposure raises the risk of cardiac malformation, particularly Ebstein anomaly — so the conversation matters for both agents, but only valproate carries a boxed fetal-risk restriction. Caffeine (A) is worth addressing in psychoeducation, where patients "are encouraged to avoid stimulants, eg, caffeine," but it does not change agent selection. A family history of hypertension (C) and regular exercise (D) are not sourced as agent-selection factors here; exercise is recommended for everyone with bipolar disorder because it "helps with depression and anxiety, promotes better sleep, and is healthy for the heart and brain."

Common questions

What causes bipolar disorder?
Common causes and risk factors include heritability — twin and family heritability estimates of 60% to 85%, up to 80% of monozygotic twins are concordant, and almost two-thirds of patients have at least one close relative with bipolar disorder or unipolar depression, age — onset most commonly in adolescence and early adulthood: one systematic review found the largest group beginning at 14–21 years, us annual prevalence is highest at 18–29 years, and onset after 60 is rare, early-life adversity — childhood trauma, maltreatment, parental loss or severe psychosocial stress, linked to earlier onset, a more severe course and more comorbidity, other named life events — childbirth, divorce, unemployment, disability and early parental loss, a stressful life event — more than 60% of patients report at least one in the 6 months before a manic or depressive episode, and others.
What are the early signs of bipolar disorder?
Early findings include Decreased need for sleep — feeling rested after about three hours.
Which findings should a nurse report immediately in bipolar disorder?
Report immediately: Irritability, aggression and property damage rather than euphoria, Not eating or sleeping for days with physical exhaustion, Manic psychosis — hallucinations and delusions appearing only within a mood episode, Suicidal ideation during a depressive episode, Vomiting, diarrhea, drowsiness, coarse tremor, slurred speech or unsteady gait in a patient on lithium, and others. These signal deterioration that needs rapid intervention.
What actually separates mania from hypomania?
Three things, and duration is only one of them. Severity — manic symptoms disrupt work or social functioning or need hospital admission, whereas hypomania does not cause major impairment. Psychosis — hypomania has no psychosis; if psychosis is present, the episode is mania by definition. Duration — at least 7 consecutive days for mania against at least 4 consecutive days for hypomania. Then the override that decides borderline cases: if the symptoms require hospitalization, the episode counts as mania rather than hypomania, even when it has lasted less than a week. Both episodes need three or more of the seven criteria symptoms — four if the mood is irritable rather than elevated — and hypomania must still involve a clear change in functioning that is out of character for the person and noticeable to others.
Why does a stomach bug matter so much for someone on lithium?
Because lithium travels the sodium pathway. It is "neither protein-bound nor metabolized and is almost entirely eliminated by renal excretion," and "the proximal tubule reabsorbs 80% of it via sodium transport pathways." When vomiting and diarrhea deplete volume and sodium, the kidney conserves sodium — and because it cannot tell the two apart, it conserves lithium too, so the serum level climbs with no change in dose. That is why "even minor changes in volume status, renal perfusion, or sodium balance can produce clinically significant changes in serum lithium concentrations," and why toxicity most commonly results from reduced renal clearance rather than excessive ingestion. The teaching that follows is consistency, not restriction: "drastic reduction in sodium can lead to lithium toxicity, and a drastic increase in sodium intake can lead to sub-therapeutic lithium." Take particular care during illness with vomiting or diarrhea, hot weather, or strenuous physical activity — and remember that NSAIDs, thiazides, ACE inhibitors and angiotensin receptor blockers do the same thing pharmacologically.
Why is bipolar disorder so often diagnosed as depression first?
Because "cross-sectionally, bipolar depression is typically indistinguishable from unipolar depression," and the illness so often opens with depression — so depression is usually what brings the patient in, and it looks identical. The result is quantified: current literature reports "an average delay of 5 to 10 years between first psychiatric contact and correct diagnosis." Only the history separates them: "the most critical diagnostic task is the systematic elicitation of past manic or hypomanic episodes, as these are often not spontaneously reported by patients." Features that raise suspicion: depression beginning early, especially before age 25; recurrent, high-frequency depressive episodes; psychotic features; postpartum episodes; a strong family history of bipolar disorder; and antidepressant-associated mood switching. Screening helps only partly — the Mood Disorders Questionnaire has 80% sensitivity and 70% specificity, and a positive result should prompt a structured clinical interview, not a diagnosis.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.